|
|
|
C-reactive
protein: RIO Lipids
|
|
Chronic, low-grade
inflammation is increasingly being implicated in the pathophysiology of
atherogenesis in the setting of abdominal obesity (Lee YH, 2005). C-reactive
protein (CRP) is a systemic marker of inflammation. Thus, interventions that
reduce CRP levels are potentially antiatherogenic (Lee YH, 2005).
|
|
Data from RIO Lipids
(ITT population) show that 1 year of treatment with rimonabant 20 mg reduced
levels of CRP significantly relative to placebo.
|
|
The
anti-inflammatory effects of rimonabant on CRP, and other parameters, such as
adiponectin, lipids and insulin resistance, highlight the efficacy of this
new approach to reducing multiple metabolic and cardiovascular risk factors.
|